[go: up one dir, main page]

PH12014502834B1 - Pharmaceutical form for extended release of active substances - Google Patents

Pharmaceutical form for extended release of active substances

Info

Publication number
PH12014502834B1
PH12014502834B1 PH12014502834A PH12014502834A PH12014502834B1 PH 12014502834 B1 PH12014502834 B1 PH 12014502834B1 PH 12014502834 A PH12014502834 A PH 12014502834A PH 12014502834 A PH12014502834 A PH 12014502834A PH 12014502834 B1 PH12014502834 B1 PH 12014502834B1
Authority
PH
Philippines
Prior art keywords
pharmaceutical form
active substances
extended release
active substance
release
Prior art date
Application number
PH12014502834A
Other versions
PH12014502834A1 (en
Inventor
Gernot Francas
Karl-Heinz Przyklenk
Original Assignee
Hennig Arzneimittel Gmbh And Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hennig Arzneimittel Gmbh And Co Kg filed Critical Hennig Arzneimittel Gmbh And Co Kg
Publication of PH12014502834A1 publication Critical patent/PH12014502834A1/en
Publication of PH12014502834B1 publication Critical patent/PH12014502834B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical form is described, which makes it possible to uniformly release an active substance over an extended period of time. The pharmaceutical form comprises an emulsifier with a polyalkylene oxide structural motif. The pharmaceutical form is suitable for releasing a second active substance alongside the first active substance. A uniform release is achieved even if the two active substances have completely different properties in terms of solubility. A production method for the pharmaceutical form and the use thereof are also described.
PH12014502834A 2012-06-25 2014-12-19 Pharmaceutical form for extended release of active substances PH12014502834B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012105512.2A DE102012105512A1 (en) 2012-06-25 2012-06-25 Pharmaceutical form for prolonged release of active ingredients
PCT/EP2013/063163 WO2014001268A1 (en) 2012-06-25 2013-06-24 Pharmaceutical form for extended release of active substances

Publications (2)

Publication Number Publication Date
PH12014502834A1 PH12014502834A1 (en) 2015-02-02
PH12014502834B1 true PH12014502834B1 (en) 2019-12-04

Family

ID=48670585

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502834A PH12014502834B1 (en) 2012-06-25 2014-12-19 Pharmaceutical form for extended release of active substances

Country Status (22)

Country Link
EP (1) EP2863891B1 (en)
KR (1) KR102160837B1 (en)
AU (1) AU2013283474B2 (en)
BR (1) BR112014032583B1 (en)
CA (1) CA2876294C (en)
CO (1) CO7240370A2 (en)
DE (1) DE102012105512A1 (en)
EA (2) EA035815B1 (en)
ES (1) ES2817248T3 (en)
HR (1) HRP20201534T1 (en)
HU (1) HUE050945T2 (en)
IL (1) IL236465B (en)
IN (1) IN2014MN02511A (en)
LT (1) LT2863891T (en)
MX (1) MX371143B (en)
PH (1) PH12014502834B1 (en)
PL (1) PL2863891T3 (en)
PT (1) PT2863891T (en)
RS (1) RS60872B1 (en)
SI (1) SI2863891T1 (en)
UA (1) UA116776C2 (en)
WO (1) WO2014001268A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
SI2959887T1 (en) * 2014-06-26 2019-04-30 Hennig Arzneimittel Gmbh&Co. Kg Medication for treating dizziness due to various causes
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
KR101625344B1 (en) * 2015-12-21 2016-06-08 주식회사 유영제약 Pharmaceutical compositions comprising celecoxib and duloxetine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
JP2001520984A (en) * 1997-10-27 2001-11-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Solid-state solvents and solid dispersions of poorly water-soluble drugs
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1701703B1 (en) * 2003-12-31 2011-03-09 Bend Research, Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102005014141B4 (en) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablet-shaped delayed-release preparation against dizziness
US20070135435A1 (en) * 2005-11-02 2007-06-14 Xiangping Qian Certain chemical entities, compositions, and methods
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
CN101049309A (en) * 2006-04-03 2007-10-10 陈茜 Cinnarizine drop pills, and preparation method
DK2200588T3 (en) * 2007-09-25 2019-07-01 Solubest Ltd COMPOSITIONS CONCERNING LIPOFILE ACTIVE RELATIONS AND METHOD OF PRODUCTION THEREOF
EP2229151B1 (en) * 2007-12-12 2012-08-08 Basf Se Salts of active ingredients with polymeric counter-ions
KR20140014401A (en) * 2009-06-11 2014-02-06 포토큐어 에이에스에이 Solid compositions comprising 5-aminolevulinic acid
WO2011024029A1 (en) * 2009-08-24 2011-03-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Fast disintegrating dosage forms of cinnarizine and dimenhydrinate combination
DE102011051308A1 (en) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Manufacturing process and dosage form
DE102011051304A1 (en) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg drug matrix
DE102011053068A1 (en) * 2011-08-29 2013-02-28 Hennig Arzneimittel Gmbh & Co. Kg Dosage form with stabilized active substance particles

Also Published As

Publication number Publication date
IN2014MN02511A (en) 2015-07-17
EA035815B1 (en) 2020-08-14
PL2863891T3 (en) 2021-01-25
MX2014015642A (en) 2015-08-05
SI2863891T1 (en) 2020-11-30
HRP20201534T1 (en) 2021-02-19
MX371143B (en) 2020-01-20
IL236465B (en) 2020-06-30
HUE050945T2 (en) 2021-01-28
IL236465A0 (en) 2015-02-26
AU2013283474B2 (en) 2017-12-14
LT2863891T (en) 2020-12-10
EP2863891B1 (en) 2020-08-26
WO2014001268A1 (en) 2014-01-03
CA2876294A1 (en) 2014-01-03
CO7240370A2 (en) 2015-04-17
AU2013283474A1 (en) 2015-01-29
PT2863891T (en) 2020-09-25
EA028064B1 (en) 2017-10-31
ES2817248T3 (en) 2021-04-06
KR102160837B1 (en) 2020-09-29
BR112014032583B1 (en) 2022-05-17
UA116776C2 (en) 2018-05-10
EP2863891A1 (en) 2015-04-29
CA2876294C (en) 2020-09-08
DE102012105512A1 (en) 2014-04-24
PH12014502834A1 (en) 2015-02-02
EA201792143A1 (en) 2018-05-31
KR20150041612A (en) 2015-04-16
BR112014032583A2 (en) 2017-06-27
EA201500043A1 (en) 2015-09-30
RS60872B1 (en) 2020-11-30
BR112014032583A8 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
PH12014502834A1 (en) Pharmaceutical form for extended release of active substances
EP2981612A4 (en) Compositions and methods for in vivo excision of hiv-1 proviral dna
EP3222278A4 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
CL2015001020A1 (en) Compounds derived from 4-carboxamido-isoindolinone, selective inhibitors of parp-1; Preparation process; pharmaceutical composition; an in vitro method; a product; and its use as a medicine with antineoplastic activity
CL2014003165A1 (en) Improved process for the preparation of treprostinil and derivatives thereof.
MX2021001231A (en) Heterocyclic compounds and their uses.
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
CL2012003075A1 (en) Pharmaceutical composition in pazopanib solution, stable and for ophthalmic use; method for the preparation of said solution.
EP3206706A4 (en) Stable injectable composition of pharmaceutically active agents and process for its preparation
EP3072536A4 (en) Hydrophilic electrospinning biological composite stent material used for tissue regeneration and preparation method and application thereof
PH12015502535B1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
EP3235512A4 (en) Method using polyethylene glycol to prepare fibroin nano/microspheres, and application of method in controlled drug release
MX2015012416A (en) Heterocyclic compounds and their uses.
MY191875A (en) Solid dosage form
PT2736488E (en) Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
PH12015502556A1 (en) Modified release formulation
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX2014012164A (en) Compositions containing probiotics and a bee pollen/clay complex, preparation method thereof and uses of same in nutrition and therapeutics.
EP2552426A4 (en) DEVICE FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES IN VAGINA
IL246525B (en) Pomegranate cell culture and methods for its preparation and use
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
MX361407B (en) Hydrocortisone controlled release formulation.
WO2013190509A3 (en) Preparation of intermediates of boceprevir
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition
CL2015000354A1 (en) Compounds derived from pyridine; Preparation process; pharmaceutical composition; and use in the treatment or prophylaxis of diabetes, atherosclerosis, among others.